Blog
RSS FeedPosted by Michael Wonder on 20 May 2019
Korean Government to reduce biopharmaceutical approval period to half
20 May 2019 - The Korean government plans to reduce by half the current one and a half years of ...
Posted by Michael Wonder on 07 May 2019
Celgene’s myelodysplastic syndrome treatment gets more insurance benefits
7 May 2019 - The Ministry of Health and Welfare has granted additional reimbursement to Celgene’s multiple myeloma drug, Revlimid (ingredient: ...
Posted by Michael Wonder on 07 May 2019
Roche agreed, MSD and BMS should, too
7 May 2019 - Immunotherapies have become so effective and popular that some cancer patients were cured. However, they are ...
Posted by Michael Wonder on 10 Apr 2019
Biogen’s orphan drug Spinraza to get reimbursement
9 April 2019 - Biogen’s Spinraza (ingredient: nusinersen), a treatment for spinal muscular atrophy (SMA), started to receive insurance benefits as ...
Posted by Michael Wonder on 25 Mar 2019
HIRA puts brakes on Gilead’s AIDS treatment receiving reimbursement
22 March 2019 - The reimbursement plan for Gilead Science Korea’s Biktarvy, an acquired immune deficiency syndrome (AIDS) treatment, has been ...
Posted by Michael Wonder on 18 Mar 2019
Reimbursement for orphan drug Spinraza imminent
18 March 2019 - Biogen’s Spinraza (nusinersen), a treatment for spinal muscular atrophy, is likely to obtain reimbursement as early ...
Posted by Michael Wonder on 27 Feb 2019
Korea’s 30th novel drug K-Cab to get insurance benefit from March
27 February 2019 - Korea’s 30th novel medicine K-Cab Tab. (tegoprazan) will receive insurance coverage, eight months after winning approval, the ...
Posted by Michael Wonder on 26 Feb 2019
Lung cancer second treatment Alunbrig likely to get insurance coverage
25 February 2019 - The National Health Insurance Service’s drug price assessment committee recently evaluated Takeda’s Alunbrig (briganitib) as eligible ...